MTOR and breast carcinoma: TAMs-derived products can mediate the activation of PI3K/Akt/mTOR, which, in turn, is associated with drug resistance cancer.For example, enhanced CC‐chemokine ligand 2 (CCL2) secretionby TAMs increases endocrine resistance in breast cancer cells via activation of the PI3K/Akt/mTOR signaling pathway.